[1] Zhang P, Wu SK, Wang Y, et al.  p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective study[J]. Oncol Lett, 2015, 9(1): 113-118.   doi: 10.3892/ol.2014.2631
[2] Chen SN, Tang YH, Tan YX, et al.  EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2[J]. Carcinogenesis, 2020, 41(6): 723-733.   doi: 10.1093/carcin/bgz180
[3]

Bossi P, Resteghini C, Paielli N, et al. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma[J/OL]. Oncotarget, 2016, 7(45): 74362−74379[2020-07-08]. https://pubmed.ncbi.nlm.nih.gov/27556186. DOI: 10.18632/oncotarget.11413.
[4] Lee J, Lee EJ, Moon SH, et al.  Strong association of epidermal growth factor receptor status with breast cancer FDG uptake[J]. Eur J Nucl Med Mol Imaging, 2017, 44(9): 1438-1447.   doi: 10.1007/s00259-017-3705-5
[5] Pan JJ, Ng WT, Zong JF, et al.  Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy[J]. Cancer, 2016, 122(4): 546-558.   doi: 10.1002/cncr.29795
[6] Thompson LDR, Franchi A.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base[J]. Virchows Arch, 2018, 472(3): 315-330.   doi: 10.1007/s00428-017-2116-0
[7] Anderson CM, Chang T, Graham MM, et al.  Change of maximum standardized uptake value slope in dynamic triphasic[18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial[J]. Int J Radiat Oncol Biol Phys, 2015, 91(3): 472-479.   doi: 10.1016/j.ijrobp.2014.11.002
[8] 许良中, 杨文涛.  免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996, 6(4): 229-231.   doi: 10.19401/j.cnki.1007-3639.1996.04.001
Xu LZ, Yang WT.  Criteria of immunohistochemical reaction results[J]. China Oncol, 1996, 6(4): 229-231.   doi: 10.19401/j.cnki.1007-3639.1996.04.001
[9] 王勇, 吴波, 孙华丽, 等.  鼻咽癌EGFR、HLA-F表达水平及调强放疗预后的影响因素分析[J]. 浙江医学, 2019, 41(17): 1826-1830.   doi: 10.12056/j.issn.1006-2785.2019.41.17.2018-2721
Wang Y, Wu B, Sun HL, et al.  Expression of EGFR and HLA-F in nasopharyngeal carcinoma and their prognostic value[J]. Zhejiang Med J, 2019, 41(17): 1826-1830.   doi: 10.12056/j.issn.1006-2785.2019.41.17.2018-2721
[10]

Wang X, Niu HT, Fan QX, et al. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma[J/OL]. Oncotarget, 2016, 7(17): 24744−24751[2020-07-08]. https://pubmed.ncbi.nlm.nih.gov/27013591. DOI: 10.18632/oncotarget.8271.
[11] 孟谊, 杨杨, 樊祥山, 等.  VEGF、EGFR的表达与非小细胞肺癌生物学行为的相关性[J]. 现代肿瘤医学, 2015, 23(5): 633-636.   doi: 10.3969/j.issn.1672-4992.2015.05.16
Meng Y, Yang Y, Fan XS, et al.  The correlation between expressions of VEGF and EGFR and biological behavior in non-small cell lung cancer (NSCLC)[J]. J Mod Oncol, 2015, 23(5): 633-636.   doi: 10.3969/j.issn.1672-4992.2015.05.16
[12] 王华, 王志红.  结直肠癌中EGFR、HER-2及PTEN的表达及临床意义[J]. 中国卫生标准管理, 2017, 8(14): 128-131.   doi: 10.3969/j.issn.1674-9316.2017.14.072
Wang H, Wang ZH.  Expression and clinical significance of EGFR, HER-2 and PTEN in colorectal carcinoma[J]. China Health Stand Manage, 2017, 8(14): 128-131.   doi: 10.3969/j.issn.1674-9316.2017.14.072
[13] 于剑飞, 崔慧林, 王宏卫.  尼妥珠单抗联合调强放疗与吡柔比星化疗对EGFR阳性晚期鼻咽癌的疗效分析[J]. 实用癌症杂志, 2020, 35(4): 566-569.   doi: 10.3969/j.issn.1001-5930.2020.04.012
Yu JF, Cui HL, Wang HW.  Therapeutic effect of nimotuzumab combined with intensity-modulated radiotherapy and pirarubicin chemotherapy on EGFR-positive advanced nasopharyngeal carcinoma[J]. Pract J Cancer, 2020, 35(4): 566-569.   doi: 10.3969/j.issn.1001-5930.2020.04.012
[14]

You R, Hua YJ, Liu YP, et al. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage Ⅱ-Ⅳb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up[J/OL]. Theranostics, 2017, 7(8): 2314−2324[2020-07-08]. https://pubmed.ncbi.nlm.nih.gov/28740554. DOI: 10.7150/thno.19710.
[15] Huang P, Liu XG, Song H, et al. Correlation between the expression of EGFR and 18F-FDG-PET SUVmax in non-small cell lung cancer[J]. 现代生物医学进展, 2011, 11(8): 1479−1483. DOI: 10.13241/j.cnki.pmb.2011.08.046.
[16] 孙新儒, 胡莹莹, 张旭, 等.  18F-FDG PET/CT SUV在鼻咽癌T分期中的价值[J]. 中山大学学报: 医学科学版, 2010, 31(4): 535-539.   doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2010.0114
Sun XR, Hu YY, Zhang X, et al.  Value of 18F-FDG PET/CT SUV in T stages of nasopharyngeal carcinoma[J]. J Sun Yat-Sen Univ (Med Sci), 2010, 31(4): 535-539.   doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2010.0114
[17] Kaneko Y, Murray WK, Link E, et al.  Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer[J]. J Nucl Med, 2015, 56(4): 523-529.   doi: 10.2967/jnumed.114.150946
[18] 吕清湖, 唐明灯, 林端瑜, 等.  原发鼻咽淋巴瘤与鼻咽癌的18F-FDG PET/CT诊断与鉴别[J]. 国际放射医学核医学杂志, 2017, 41(3): 166-172.   doi: 10.3760/cma.j.issn.1673-4114.2017.03.002
Lyu QH, Tang MD, Lin DY, et al.  Value of 18F-FDG PET/CT examination in the differential diagnosis of primary nasopharyngeal lymphoma and nasopharyngeal carcinoma[J]. Int J Radiat Med Nucl Med, 2017, 41(3): 166-172.   doi: 10.3760/cma.j.issn.1673-4114.2017.03.002
[19] Lee JW, Kang CM, Choi HJ, et al.  Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer[J]. J Nucl Med, 2014, 55(6): 898-904.   doi: 10.2967/jnumed.113.131847
[20]

杨易, 张依凡, 展凤麟, 等. 18F-FDG PET/CT代谢参数在诊断鼻咽癌及预测其转移中的应用价值[J/OL]. 临床医药文献电子杂志, 2020, 7(22): 8−10[2020-07-08]. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_lcyydzzz202022005. DOI: 10.16281/j.cnki.jocml.2020.22.005.

Yang Y, Zhang YF, Zhan FL, et al. The application value of 18F-FDG PET/CT metabolic parameters in the diagnosis and prediction of nasopharyngeal carcinoma[J/OL]. Electron J Clin Med Lit, 2020, 7(22): 8−10 [2020-07-08]. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_lcyydzzz202022005. DOI: 10.16281/j.cnki.jocml.2020.22.005.
[21] 张倩, 辛军, 李红.  18F-FDG PET/CT显像半定量参数MTV、TLG联合SUV在乳腺癌诊断中的应用价值[J]. 中国临床医学影像杂志, 2016, 27(9): 620-624.
Zhang Q, Xin J, Li H.  Clinical value of 18F-FDG uptake, described by metabolic tumor volume, total lesion glycolysis and standard uptake values in breast cancer[J]. J China Clin Med Imaging, 2016, 27(9): 620-624.
[22] 姜阳, 马晓伟, 董楚宁, 等.  基于18F-FDG PET-CT代谢参数的风险模型对非小细胞肺癌EGFR基因突变的预测价值及效能评价[J]. 中华放射学杂志, 2020, 54(7): 688-693.   doi: 10.3760/cma.j.cn112149-20190731-00652
Jiang Y, Ma XW, Dong CN, et al.  The predictive value and efficacy of the risk model based on the metabolic parameters of 18F-FDG PET-CT for EGFR gene mutations in non-small cell lung cancer[J]. Chin J Radiol, 2020, 54(7): 688-693.   doi: 10.3760/cma.j.cn112149-20190731-00652
[23] Surov A, Meyer HJ, Höhn AK, et al.  Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer[J]. Cancer Biomark, 2019, 24(1): 135-140.   doi: 10.3233/CBM-182019
[24] Lin YC, Chen RY, Chen SW, et al.  Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes[J]. Clin Otolaryngol, 2017, 42(3): 608-619.   doi: 10.1111/coa.12783
[25]

Ruan L, Li XH, Wan XX, et al. Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics[J/OL]. Proteome Sci, 2011, 9(1): 35[2020-07-08]. https://pubmed.ncbi.nlm.nih.gov/21711528. DOI: 10.1186/1477-5956-9-35.
[26] 奚少彦, 吴秋良, 宗永生, 等.  环氧化酶-2、表皮生长因子受体与Ki-67在鼻咽癌中表达的临床病理意义[J]. 广东医学, 2012, 33(10): 1422-1425.   doi: 10.13820/j.cnki.gdyx.2012.10.064
Xi SY, Wu QL, Zong YS, et al.  Clinicopathological significance of cox-2 epidermal growth factor receptor and Ki-67 expression in nasopharyngeal carcinoma[J]. Guangdong Med J, 2012, 33(10): 1422-1425.   doi: 10.13820/j.cnki.gdyx.2012.10.064